Healthcare

Disposal of EcoTECH

2018-02-28T17:00:25+00:00

HMT advised the shareholders of ecoTECH on their disposal to Climate Energy Limited, a leading carbon reduction management agent. Founded by Christine Hynes and David Alderton, Ecotech designs and builds ecoTECH ZCBS, a UK Zero Carbon off-site manufactured complete building envelope, which complies with the UK‘s new Governments building regulations. ecoTECH ZCBS is leading the market with a cost on par with that of traditional build and a capacity to deliver up to 5,000 homes per annum. Climate [...]

Imperial Innovations Group PLC Invests in Stanmore Implants

2017-11-29T21:32:46+00:00

    HMT advised Imperial Innovations, the UK's leading technology commercialisation and investment company, on its £4 million investment in Stanmore Implants. Stanmore Implants is a specialist in the design and manufacture of patient specific implants for complex orthopaedic reconstructions. Stamnore currently focuses on orthopaedic oncology, and complex primary and secondary revisions in the upper limb, lower limb and pelvis, with a custom design and manufacture service. The proceeds will be used to expand Stanmore's US and UK [...]

Disposal of in4tek Limited to Civica Group Ltd

2017-11-29T22:03:04+00:00

HMT advised the shareholders of in4tek Limited on its disposal to Civica Group Ltd. in4tek, based in Altrincham, specialises in application software and related services for the health and social care sectors. Its integrated product suite, which enables the management of all aspects of community-based care, is used by health service providers and local authorities across the UK and Canada, including within Connecting for Health, the NHS National Programme for IT in England. The company was owned by [...]

Wound Solutions completes round of fundraising

2017-11-29T22:06:14+00:00

Wound Solutions Limited, exclusively advised by HMT, have successfully raised £2.5m in development funding from both new and existing investors. This will enable Wound Solutions to bring to market its initial product. Wound Solutions is involved in developing an innovative solution for the healing of chronic wounds by combining the benefits of electrotherapy with the ability for continuous monitoring. Initial studies have shown strong potential for Wound Solutions' first product and it is already in the midst of [...]

Acquisition by Premier Research Arizona LLC of Pivotal Research Centers Inc

2017-11-29T22:15:27+00:00

  HMT advised Premier Research Group (“PRG”), an international pharmaceutical services group, on the acquisition of Pivotal Research Centers Inc (“Pivotal”), funded by ECI Partners. The acquisition continues PRG’s buy and build growth strategy to build a leading international contract research organisation, whilst also complimenting PRG’s existing offering in the market. Pivotal is well established as a clinical research business based in Phoenix Arizona, with two further sites in Mesa and Salt Lake City. Today the business has [...]

Acquisition of Healthcare Software Systems Limited

2017-11-29T23:00:47+00:00

HMT acted as reporting accountants for Sunset Dawn Limited on its acquisition of Healthcare Software Systems Limited. HSS was established in 1987 and is now a leading provider of radiology information management solutions in the healthcare industry.  This has been brought about by the development and supply of specialist software, namely ‘Computerised Radiology Information System’ (“CRIS”) under the National Programme for IT launched by the National Health Service in 2002. CRIS has now been embedded into around 150 [...]

Premier Research plc acquired Scirex Corporation Group for up to £20 million

2017-12-08T16:04:37+00:00

HMT advised Premier Research Group plc (“PRG”), an international pharmaceutical services group, on the acquisition of the Scirex Corporation Group (“Scirex”) for up to £20 million. Scirex, a subsidiary of Omnicom Inc, the global leader in marketing communications, is a full service contract research organisation (“CRO”) specialising in providing outsourced clinical services to a number of pharmaceutical areas. It specialises in trials from Phase I through to Phase IV, specialising in analgesia (CNS), general medicine (e.g. cardiovascular) and [...]

Acquisition of Apollo Medical Systems Limited

2017-11-29T23:26:47+00:00

  I HMT acted as reporting accountants for Sunset Dawn Limited on its acquisition of Apollo Medical Systems Limited (“Apollo”). Apollo was established in 2000 and is now a well-established and successful provider of IT solution to the National Health Service (“NHS”). This has been brought about by the development and supply of specialist software, SQL suite, which has now effectively been embedded into around 90% of GP surgeries. HMT commented: “We consider that in light of the [...]

Premier Research Plc acquired PharmData Inc for up to £12.0 million and Imform GmbH for up to £4.5 million

2017-12-08T16:17:34+00:00

HMT advised Premier Research Group plc (“PRG”) an international pharmaceutical services group on the acquisition of Pharmdata Inc (“PharmData”) and Imform GmbH (“Imform”) for up to £12.0 million and £4.5 million respectively. PharmData is a Contract Research Organisation (“CRO”) that specialises in clinical data management, statistical analysis, medical writing, electronic archiving and project management services for the pharmaceutical, biotechnology, and medical device industries.  The business, which was set up in 1994, is based in Atlanta, USA and employs [...]

Premier Research Plc acquired EPA Euro Pharma GmbH for £3.2 million

2017-12-08T16:27:39+00:00

HMT advised Premier Research Group Plc (“PRG”) an international pharmaceutical services group on the acquisition of EPA Euro Pharma GmbH (“EPA”) for £3.2 million. EPA is a contract research organisation (“CRO”), based near Frankfurt, providing a broad range of outsourced clinical services to the biotechnology and pharmaceutical industries. The majority of EPA orders are with German pharmaceutical and biotechnology companies. However, EPA also has contracts with several of the world’s largest multinational pharmaceutical groups. Dr Simon Yaxley, Chief [...]

Go to Top